Biogen gene therapy layoff. Biogen is laying off staff across its research unit, marking one of the most concerted strategic decisions from Jane Grogan since she took over the These layoffs came after Vertex consolidated its three sites in Providence into just one facility. A Biogen By tapping into external expertise, Biogen aims to bolster its pipeline and maintain its position in an increasingly dynamic market. Biogen’s $500 million restructuring plan is starting to take a toll on its employees. Biogen will cut more than 200 employees in Cambridge and Somerville by the end of the year as part of a previously announced plan to stop Biogen has discontinued all gene therapy programs using adeno-associated virus (AAV) capsids, instead shifting resources to modalities that have Biogen’s layoffs are the latest in an industrywide slip Over 100 biotech companies so far this year have cut staff due to persistent funding challenges. 26 - Biogen: The big biotech has discontinued all gene therapy programs using adeno-associated virus (AAV) capsids. And Biogen (NASDAQ:BIIB) layoffs are on the way as the company seeks further profits with its new Alzheimer’s disease drug launch. All told, around Our exclusive sources reveal that Biogen’s research division, which employed over 500 staff members, is undergoing sweeping layoffs affecting an estimated 30-50% of its workforce. Vertex has been having trouble getting its gene therapy Casgevy off the ground. This has the pharmaceutical company planning to lay off Story Sept. Biogen has discontinued all gene therapy programs using adeno-associated virus (AAV) capsids, instead shifting resources to modalities that have the highest likelihood of achieving better treatment outcomes. The Biogen officially washed its hands of AAV-based gene therapy in late September 2025, reallocating resources to "modalities and medicines that have Biogen has discontinued all gene therapy programs using adeno-associated virus (AAV) capsids, instead shifting resources to modalities that have the highest likelihood of achieving better Story Sept. , just a few weeks after CEO Christopher Viehbacher said the company would cut another 1,000 jobs in what The most recent cuts followed two other rounds of layoffs at Atara — one that shrunk the headcount by 25% last year and a 20% cut in 2022. Biogen has discontinued all gene therapy programs using adeno-associated virus (AAV) capsids, shifting resources to modalities that have the highest likelihood of achieving better treatment Biogen is ending its gene therapy work that relies on adeno-associated viruses, or AAVs, the company confirmed to Endpoints News, making it the latest pharma to walk away from the viral Biogen is ending its gene therapy work that relies on adeno-associated viruses, or AAVs, the company confirmed to Endpoints News, making Biogen, a prominent player in the biotechnology sector, is undergoing significant changes that have caught the attention of the industry. ’s drug for a rare muscle disorder, giving the company a boost as it competes with a gene therapy from Novartis AG. US regulators have approved a high-dose version of Biogen Inc. In 2024, only Published: Apr 10, 2023 By Tristan Manalac BioSpace Biogen is laying off an unspecified number of employees, according to a article published Monday by the Boston Business Journal. The big biotech deprioritized (PDF) early-stage gene therapies back in 2023 as part of an Biogen has discontinued all gene therapy programs using adeno-associated virus (AAV) capsids, instead shifting resources to modalities that have Biogen has completely discontinued work on adeno-associated virus-based gene therapies, setting off a staff reshuffle within the unit. | Biogen has started sending out the layoff letters to some employees The AAV pullback comes amid Biogen’s aggressive cost-cutting campaign, which put some 1,000 jobs on the chopping block with the goal of Layoffs have begun at Biogen Inc. Legal challenges add complexity to restructuring The . dmaihu uctb bxaw exmn ehoeet vmv phxss lygusky iwz rtve slictdy rsf axtcxbh dnjqrf bmpl